MemoryGel™ – BiotechReality – Information Intelligence System for Biopharma

Johnson & Johnson MedTech has announced the introduction of its MENTOR™ MemoryGel™ Enhance Breast Implants, which are intended to fill a major gap in reconstructive solutions for women with larger breasts after breast cancer surgery. This new series of implants, cleared in November 2024 and recently on the U.S. market, is designed to bring individualized results to the roughly 15% of patients who've undergone mastectomies and before now have had few options for implants of equal sizes. The MENTOR™ MemoryGel™ Enhance implants come in sizes from 930 cc to 1445 cc. Johnson & Johnson MedTech is delivering on our promise to make breast reconstruction more inclusive, supportive, and empowering for every woman, Too many women have been left without options that helped them achieve their desired outcomes. The availability of MemoryGel™ Enhance Implants brings us closer to addressing this gap – because every woman deserves access to reconstruction options that reflect her body and her goals. Alenka Brzulja The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy. Johnson & Johnson MedTech stresses that the new product line provides customized outcomes without sacrificing aesthetic results. Clinical trial results of the Athena Study validate the effectiveness and patient satisfaction with these implants. The study reported a very high overall rate of patient satisfaction at 96%. In addition, the trial showed low complication rates and achieved significant patient well-being improvements for those who underwent the implants. Nevertheless, it should be noted that breast implants are not lifetime devices. They come with some risks, such as possible complications and the formation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Patients who are thinking about this reconstructive procedure should sit down with their healthcare provider and discuss all possible risks and benefits. Source: Johnson & Johnson Last Modified:

Tag: MemoryGel™

Johnson & Johnson Launches MENTOR™ MemoryGel™ Breast Implants for Reconstruction Patients

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment